Are you looking for promising investment opportunities in the financial market? Here are five stocks that have been recently added to the Zacks Rank #1 (Strong Buy) List, which could be worth your attention:
Intapp, Inc. (INTA)
Intapp, Inc. is a company that provides industry-specific, cloud-based software solutions for professional and financial services firms. Its Zacks Consensus Estimate for current year earnings has seen a significant increase of 35.3% over the last 60 days. With its innovative software solutions, Intapp is poised for success in the current market.
Nu Holdings Ltd. (NU)
Nu Holdings Ltd. is a digital banking and technology platform provider. The company has experienced a 23.5% increase in its Zacks Consensus Estimate for current year earnings over the past 60 days. With the growing demand for digital banking solutions, Nu Holdings Ltd. is well-positioned to capitalize on this trend.
Enlivex Therapeutics Ltd. (ENLV)
Enlivex Therapeutics Ltd. is a clinical stage immunotherapy company. Its Zacks Consensus Estimate for current year earnings has increased by 19.1% in the last 60 days. With its focus on immunotherapy, Enlivex Therapeutics Ltd. has the potential to make a significant impact in the healthcare industry.
Vericel Corporation (VCEL)
Vericel Corporation develops patient-specific expanded cellular therapies for the treatment of severe diseases and conditions. Its Zacks Consensus Estimate for current year earnings has risen by 17.9% in the past 60 days. With its cutting-edge therapies, Vericel Corporation has the potential to revolutionize the treatment of severe diseases.
BioVie Inc. (BIVI)
BioVie Inc. is a company focused on developing drug therapies for liver disease. Its Zacks Consensus Estimate for current year earnings has increased by 12.7% over the last 60 days. As liver disease continues to be a significant health concern, BioVie Inc. is well-positioned to address this unmet medical need.
For a complete list of today’s Zacks #1 Rank (Strong Buy) stocks, you can visit Zacks.com.
Looking for the next big investment opportunity? Zacks Investment Research has identified a stock that is predicted to double in the coming months. This stock is credited with a “watershed medical breakthrough” and has a promising pipeline of projects in the liver, lungs, and blood space. Don’t miss this timely investment opportunity that has the potential to rival recent stocks that doubled in value.
To learn more about this top stock pick and get four more runner-up options, click here: Free: See Our Top Stock And 4 Runners Up.
For additional recommendations from Zacks Investment Research, you can download the report on the 7 Best Stocks for the Next 30 Days by clicking here: Click to get this free report.
Remember, investing involves risks, so it is important to do your own research and seek advice from a financial advisor before making any investment decisions.
To read this article on Zacks.com, click here: New Top Stocks for Investors: October 19th.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
